Stockscreener 앱 받기
13.28
7.70%
0.95
시간 외 거래:
13.21
-0.07
-0.53%
전일 마감가:
$12.33
열려 있는:
$12.46
하루 거래량:
116.58K
Relative Volume:
0.41
시가총액:
$495.82M
수익:
$50.00M
순이익/손실:
$-59.98M
주가수익비율:
-6.0817
EPS:
-2.1836
순현금흐름:
$-55.54M
1주 성능:
+8.67%
1개월 성능:
-15.84%
6개월 성능:
+22.28%
1년 성능:
+67.89%
1일 변동 폭
$12.46
$13.59
1주일 범위
$11.80
$13.59
52주 변동 폭
$3.35
$16.33
Contineum Therapeutics Inc Stock (CTNM) Company Profile
명칭
Contineum Therapeutics Inc
전화
(858) 333-5280
주소
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
13.28 | 460.35M | 50.00M | -59.98M | -55.54M | -2.1836 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-09-25 | 개시 | Leerink Partners | Outperform |
| 2025-06-20 | 개시 | William Blair | Outperform |
| 2024-10-22 | 개시 | Robert W. Baird | Outperform |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-30 | 개시 | Stifel | Buy |
모두보기
Contineum Therapeutics Inc 주식(CTNM)의 최신 뉴스
Contineum Therapeutics (NASDAQ:CTNM) Trading 8.7% HigherStill a Buy? - MarketBeat
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Bond Watch: Will Corvus Pharmaceuticals Inc stock go up in YEAR2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Contineum Therapeutics, Inc.Common stock (NQ: CTNM - The Chronicle-Journal
Revenue Check: Is FKWL still a buy after recent gainsStock Surge & Detailed Earnings Play Alerts - baoquankhu1.vn
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference - Defense World
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 13, 2026 - BioSpace
Contineum Therapeutics, Inc. $CTNM Shares Sold by Baker BROS. Advisors LP - MarketBeat
Baird Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - MSN
Certain Options of Contineum Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2026. - marketscreener.com
6,083,338 Class B common stock of Contineum Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2026. - marketscreener.com
Contineum’s MS drug falls short in Phase II trial - MSN
Update Recap: How sensitive is Contineum Therapeutics Inc to inflationQuarterly Profit Review & Daily Chart Pattern Signals - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Contineum Therapeutics, Inc. Class A (CTNM) and Aktis Oncology, Inc. (AKTS) - The Globe and Mail
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Contineum Therapeutics, Inc. Class A Common Stock share price - Mint
Can Contineum Therapeutics Inc. stock resist sector downturns2026 Institutional & Risk Adjusted Buy and Sell Alerts - Naître et grandir
Contineum Therapeutics (NASDAQ:CTNM) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Contineum Therapeutics (NASDAQ:CTNM) Price Target Raised to $20.00 at Robert W. Baird - MarketBeat
Stifel reiterates Buy on Contineum stock, keeps $29 price target By Investing.com - Investing.com South Africa
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Developme - PharmiWeb.com
Stifel reiterates Buy on Contineum stock, keeps $29 price target - Investing.com India
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - The National Law Review
Contineum Therapeutics (NASDAQ:CTNM) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Contineum reports Q4 EPS (49c), consensus (39c) - TipRanks
Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress - TipRanks
Contineum Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Contineum Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
CTNM: Phase 2 IPF trial dosing started, $93M raised, and cash runway extends into mid-2029 - TradingView
Contineum Therapeutics (NASDAQ: CTNM) posts Q4 loss, adds $100,000,000 at-the-market stock capacity - Stock Titan
CTNM SEC FilingsContineum Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
According to the latest public documents from the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Contineum Therapeutics Inc. has launched a new stock offering plan. - Bitget
USD News Center - University of San Diego
Contineum Therapeutics Faces Downgrade Following Clinical Trial Setback () - aktiencheck.de
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference - Business Wire
CTNMContineum Therapeutics Latest Stock News & Market Updates - Stock Titan
Contineum Therapeutics to Present at September Investor Conferences - Business Wire
Lorrain Daniel S. sells Contineum Therapeutics (CTNM) shares By Investing.com - Investing.com South Africa
Contineum Therapeutics (CTNM) CMO sells $54,220 in stock - Investing.com
Lorrain Daniel S. sells Contineum Therapeutics (CTNM) shares - Investing.com
Contineum Therapeutics (CTNM) CMO sells $54,220 in stock By Investing.com - Investing.com UK
Contineum Therapeutics (CTNM) CSO sells shares under 10b5-1 plan - Stock Titan
Contineum Therapeutics (CTNM) CMO sells 3,611 shares via 10b5-1 - Stock Titan
Beat the Market with Zacks: Spotlight on Contineum Therapeutics, Suzano, and PepsiCo - Bitget
Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus - Yahoo Finance
Earnings Beat: Is Contineum Therapeutics Inc gaining market shareJuly 2025 Momentum & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Contineum Therapeutics CSO Lorrain S. Daniel sells $130k in CTNM stock - Investing.com Nigeria
Contineum Therapeutics Inc (CTNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):